Alcanza Clinical Research has completed the acquisition of Tampa Bay Medical Research, an independent clinical research center with a nearly four-decade legacy in the Tampa Bay region. The strategic move integrates TBMR's established community presence and operational excellence with Alcanza's national network and scalable infrastructure, positioning the combined organization to accelerate clinical research and expand patient access to innovative treatment opportunities.
Founded in 1984, Tampa Bay Medical Research has completed more than 600 clinical trials across a broad spectrum of therapeutic areas for more than 70 pharmaceutical and medical device sponsors. With facilities totaling over 5000 square feet in Clearwater and Largo, TBMR has built a reputation as a trusted partner for both community participants and global sponsors seeking high-quality clinical data. The center's multidisciplinary team includes Principal Investigators, certified clinical research coordinators, and support staff who have consistently delivered patient-centric research environments.
CEO and Medical Director of TBMR, Sureka Bollepalli, MD, brings over 20 years of experience conducting NIH and industry-sponsored trials from study initiation through execution and close-out. As a board-certified endocrinologist and long-standing leader within the metabolic research community, Dr. Bollepalli's expertise will now be integrated into Alcanza's expanding network. "We are excited to begin this next chapter with Alcanza Clinical Research," said Dr. Bollepalli. "This partnership strengthens our ability to support patients, deepen community engagement, and expand access to high-quality clinical research—allowing us to advance care and improve lives together."
For Alcanza Clinical Research, the acquisition represents a significant milestone in expanding its national footprint while preserving the local expertise and personalized care that TBMR participants and sponsors have come to rely on. Carlos Orantes, CEO at Alcanza Clinical Research, emphasized that "partnering with high quality clinical research businesses and operators remains a top priority for us. We are very excited to welcome Dr. Bollepalli and her TBMR team to the Alcanza family."
The integration creates a powerful combination of TBMR's community-focused approach with Alcanza's extensive resources. Alcanza operates an integrated network of research facilities focused on bringing clinical trial opportunities involving life-changing treatments and vaccines to all patients, especially those from under-represented communities. The network includes 25 dedicated research units and additional integrated specialty clinic sites strategically located throughout the Southeast, Northeast, Southwest, Midwest, and Puerto Rico, supporting studies across all trial phases and major therapeutic areas.
This acquisition has significant implications for clinical research accessibility in the Tampa Bay region and beyond. By combining TBMR's nearly four decades of local relationships and research experience with Alcanza's national infrastructure and strategic partnerships, the organization can streamline clinical trial processes, potentially reducing the time it takes to bring new therapies to market. Patients in the region will benefit from expanded access to cutting-edge treatments through a broader portfolio of clinical trials, while pharmaceutical and medical device sponsors gain access to a more robust research platform with enhanced operational capabilities.
The consolidation reflects broader trends in the clinical research industry toward creating integrated networks that can deliver both scale and specialized expertise. As research becomes increasingly complex and patient recruitment more challenging, such strategic combinations enable more efficient trial execution while maintaining the community connections essential for diverse patient participation. More information about Alcanza Clinical Research's network and mission is available at https://alcanzaclinical.com.
